請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58832完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 紀秀華,張智芬 | |
| dc.contributor.author | Mei-Ju Ko | en |
| dc.contributor.author | 柯玫如 | zh_TW |
| dc.date.accessioned | 2021-06-16T08:33:36Z | - |
| dc.date.available | 2019-02-25 | |
| dc.date.copyright | 2014-02-25 | |
| dc.date.issued | 2013 | |
| dc.date.submitted | 2013-12-04 | |
| dc.identifier.citation | Aberer, W., Schuler, G., Stingl, G., Honigsmann, H., and Wolff, K. (1981). Ultraviolet light depletes surface markers of Langerhans cells. J Invest Dermatol 76, 202-210.
Ada, S., Seckin, D., Budakoglu, I., and Ozdemir, F.N. (2005). Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study. J Am Acad Dermatol 53, 149-151. Akiyama, T., Carstens, M.I., and Carstens, E. (2010). Enhanced scratching evoked by PAR-2 agonist and 5-HT but not histamine in a mouse model of chronic dry skin itch. Pain 151, 378-383. Akobeng, A.K. (2007). Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr 96, 644-647. Andrew, D., and Craig, A.D. (2001). Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 4, 72-77. Arora, S., Smakowski, P., Frykberg, R.G., Simeone, L.R., Freeman, R., LoGerfo, F.W., and Veves, A. (1998). Differences in foot and forearm skin microcirculation in diabetic patients with and without neuropathy. Diabetes Care 21, 1339-1344. Ashmore, S.D., Jones, C.H., Newstead, C.G., Daly, M.J., and Chrystyn, H. (2000). Ondansetron therapy for uremic pruritus in hemodialysis patients. Am J Kidney Dis 35, 827-831. Avitabile, N.A., Banka, A., and Fonseca, V.A. (2012). Glucose control and cardiovascular outcomes in individuals with diabetes mellitus: lessons learned from the megatrials. Heart Fail Clin 8, 513-522. Backonja, M., Beydoun, A., Edwards, K.R., Schwartz, S.L., Fonseca, V., Hes, M., LaMoreaux, L., and Garofalo, E. (1998). Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA: the journal of the American Medical Association 280, 1831-1836. Balaskas, E.V., Bamihas, G.I., Karamouzis, M., Voyiatzis, G., and Tourkantonis, A. (1998). Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. Nephron 78, 395-402. Balaskas, E.V., and Uldall, R.P. (1992). Erythropoietin treatment does not improve uremic pruritus. Perit Dial Int 12, 330-331. Basevi, V., Di Mario, S., Morciano, C., Nonino, F., and Magrini, N. (2011). Comment on: American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011;34(Suppl. 1):S11-S61. Diabetes Care 34, e53; author reply e54. Beckman, J.A., Creager, M.A., and Libby, P. (2002). Diabetes and atherosclerosis. JAMA: the journal of the American Medical Association 287, 2570-2581. Bell, J.K., McQueen, D.S., and Rees, J.L. (2004). Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br J Pharmacol 142, 374-380. Benedetti, A., Abrahamowicz, M., Leffondre, K., Goldberg, M.S., and Tamblyn, R. (2009). Using Generalized Additive Models to Detect and Estimate Threshold Associations. The International Journal of Biostatistics 5. Bergasa, N.V., McGee, M., Ginsburg, I.H., and Engler, D. (2006). Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology 44, 1317-1323. Berghoff, M., Kilo, S., Hilz, M.J., and Freeman, R. (2006). Differential impairment of the sudomotor and nociceptor axon-reflex in diabetic peripheral neuropathy. Muscle Nerve 33, 494-499. Bigliardi-Qi, M., Sumanovski, L.T., Buchner, S., Rufli, T., and Bigliardi, P.L. (2004). Mu-opiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology 209, 183-189. Bigliardi, P.L., Stammer, H., Jost, G., Rufli, T., Buchner, S., and Bigliardi-Qi, M. (2007). Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 56, 979-988. Biro, T., Toth, B.I., Hasko, G., Paus, R., and Pacher, P. (2009). The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci 30, 411-420. Bodo, E., Kovacs, I., Telek, A., Varga, A., Paus, R., Kovacs, L., and Biro, T. (2004). Vanilloid receptor-1 (VR1) is widely expressed on various epithelial and mesenchymal cell types of human skin. J Invest Dermatol 123, 410-413. Booken, N., Heck, M., Nicolay, J.P., Klemke, C.D., Goerdt, S., and Utikal, J. (2011). Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol 164, 665-667. Botchkarev, V.A., Metz, M., Botchkareva, N.V., Welker, P., Lommatzsch, M., Renz, H., and Paus, R. (1999). Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 act as 'epitheliotrophins' in murine skin. Lab Invest 79, 557-572. Bousquet, J., Rivory, J.P., Maheut, M., Michel, F.B., and Mion, C. (1989). Double-blind, placebo-controlled study of nicergoline in the treatment of pruritus in patients receiving maintenance hemodialysis. J Allergy Clin Immunol 83, 825-828. Brownlee, M. (2005). The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615-1625. Cadet, J., Mouret, S., Ravanat, J.L., and Douki, T. (2012). Photoinduced damage to cellular DNA: direct and photosensitized reactions. Photochem Photobiol 88, 1048-1065. Caterina, M.J., Schumacher, M.A., Tominaga, M., Rosen, T.A., Levine, J.D., and Julius, D. (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389, 816-824. Ceriello, A. (2010). Point: Postprandial Glucose Levels Are a Clinically Important Treatment Target. Diabetes Care 33, 1905-1907. Ceriello, A., Hanefeld, M., Leiter, L., Monnier, L., Moses, A., Owens, D., Tajima, N., and Tuomilehto, J. (2004). Postprandial glucose regulation and diabetic complications. Arch Intern Med 164, 2090-2095. Chan, L.S., Robinson, N., and Xu, L. (2001). Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 117, 977-983. Chang, H.Y., Hsu, C.C., Pan, W.H., Liu, W.L., Cheng, J.Y., Tseng, C.H., Bai, C.H., Yeh, W.T., and Hurng, B.S. (2010). Gender differences in trends in diabetes prevalence from 1993 to 2008 in Taiwan. Diabetes Res Clin Pract 90, 358-364. Chen, C.L., Wang, S.D., Zeng, Z.Y., Lin, K.J., Kao, S.T., Tani, T., Yu, C.K., and Wang, J.Y. (2006a). Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. J Allergy Clin Immunol 118, 105-112. Chen, H.Y., Chiu, Y.L., Hsu, S.P., Pai, M.F., Lai, C.F., Yang, J.Y., Peng, Y.S., Tsai, T.J., and Wu, K.D. (2010). Elevated C-reactive protein level in hemodialysis patients with moderate/severe uremic pruritus: a potential mediator of high overall mortality. QJM 103, 837-846. Chen, W.C., Lim, P.S., Wu, W.C., Chiu, H.C., Chen, C.H., Kuo, H.Y., Tsai, T.W., Chien, P.I., Su, Y.J., Su, Y.L., et al. (2006b). Sleep behavior disorders in a large cohort of chinese (Taiwanese) patients maintained by long-term hemodialysis. Am J Kidney Dis 48, 277-284. Chen, Y.-Y., and Tsai, T.-F. (2002). The Minimal Erythema Dose of 311 nm Narrow-band UVB in Taiwanese. Dermatol Sinica 20, 286-293. Chertow, G.M., Levin, N.W., Beck, G.J., Depner, T.A., Eggers, P.W., Gassman, J.J., Gorodetskaya, I., Greene, T., James, S., Larive, B., et al. (2010). In-center hemodialysis six times per week versus three times per week. N Engl J Med 363, 2287-2300. Chiu, Y.L., Chen, H.Y., Chuang, Y.F., Hsu, S.P., Lai, C.F., Pai, M.F., Yang, S.Y., and Peng, Y.S. (2008). Association of uraemic pruritus with inflammation and hepatitis infection in haemodialysis patients. Nephrol Dial Transplant 23, 3685-3689. Chou, F.F., Ho, J.C., Huang, S.C., and Sheen-Chen, S.M. (2000). A study on pruritus after parathyroidectomy for secondary hyperparathyroidism. J Am Coll Surg 190, 65-70. Chuang, H.H., Prescott, E.D., Kong, H., Shields, S., Jordt, S.E., Basbaum, A.I., Chao, M.V., and Julius, D. (2001). Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 411, 957-962. Clarke, P.S. (2004). Causal Analysis of Individual Change Using the Difference Score. Epidemiology 15, 414-421. Cornelissen, C., Luscher-Firzlaff, J., Baron, J.M., and Luscher, B. (2012). Signaling by IL-31 and functional consequences. Eur J Cell Biol 91, 552-566. Coven, T.R., Burack, L.H., Gilleaudeau, R., Keogh, M., Ozawa, M., and Krueger, J.G. (1997). Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol 133, 1514-1522. Cowden, J.M., Riley, J.P., Ma, J.Y., Thurmond, R.L., and Dunford, P.J. (2010a). Histamine H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of Th2 cytokines. Respir Res 11, 86. Cowden, J.M., Zhang, M., Dunford, P.J., and Thurmond, R.L. (2010b). The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J Invest Dermatol 130, 1023-1033. Cremer, B., Heimann, A., Dippel, E., and Czarnetzki, B.M. (1995). Pruritogenic effects of mitogen-stimulated peripheral blood mononuclear cells in atopic eczema. Acta Derm Venereol 75, 426-428. Dallos, A., Kiss, M., Polyanka, H., Dobozy, A., Kemeny, L., and Husz, S. (2006). Effects of the neuropeptides substance P, calcitonin gene-related peptide, vasoactive intestinal polypeptide and galanin on the production of nerve growth factor and inflammatory cytokines in cultured human keratinocytes. Neuropeptides 40, 251-263. Dambacher, J., Beigel, F., Seiderer, J., Haller, D., Goke, B., Auernhammer, C.J., and Brand, S. (2007). Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. Gut 56, 1257-1265. Dando, T.M., and Perry, C.M. (2004). Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64, 777-794. Darmani, N.A., and Pandya, D.K. (2000). Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice. J Neural Transm 107, 931-945. Darsow, U., Drzezga, A., Frisch, M., Munz, F., Weilke, F., Bartenstein, P., Schwaiger, M., and Ring, J. (2000). Processing of histamine-induced itch in the human cerebral cortex: a correlation analysis with dermal reactions. J Invest Dermatol 115, 1029-1033. Darsow, U., Scharein, E., Simon, D., Walter, G., Bromm, B., and Ring, J. (2001). New aspects of itch pathophysiology: component analysis of atopic itch using the 'Eppendorf Itch Questionnaire'. Int Arch Allergy Immunol 124, 326-331. Daugirdas, J.T. (1995). Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn. Adv Ren Replace Ther 2, 295-304. Dawn, A.G., and Yosipovitch, G. (2006). Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 54, 527-531. De Marchi, S., Cecchin, E., Villalta, D., Sepiacci, G., Santini, G., and Bartoli, E. (1992). Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 326, 969-974. Decode Study Group, the European Diabetes Epidemiology Group (2001). Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161, 397-405. Demierre, M.F., and Taverna, J. (2006). Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol 55, 543-544. Desai, N.S., Poindexter, G.B., Monthrope, Y.M., Bendeck, S.E., Swerlick, R.A., and Chen, S.C. (2008). A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol 59, 234-244. Di Marzo, V., Melck, D., Orlando, P., Bisogno, T., Zagoory, O., Bifulco, M., Vogel, Z., and De Petrocellis, L. (2001). Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 358, 249-255. Diffey, B.L. (2003). Factors affecting the choice of a ceiling on the number of exposures with TL01 ultraviolet B phototherapy. Br J Dermatol 149, 428-430. Dillon, S.R., Sprecher, C., Hammond, A., Bilsborough, J., Rosenfeld-Franklin, M., Presnell, S.R., Haugen, H.S., Maurer, M., Harder, B., Johnston, J., et al. (2004). Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nature Immunology 5, 752-760. Drivsholm, T., de Fine Olivarius, N., Nielsen, A.B., and Siersma, V. (2005). Symptoms, signs and complications in newly diagnosed type 2 diabetic patients, and their relationship to glycaemia, blood pressure and weight. Diabetologia 48, 210-214. Du, B.X., Song, Z.M., Wang, K., Zhang, H., Xu, F.Y., Zou, Z., and Shi, X.Y. (2013). Butorphanol prevents morphine-induced pruritus without increasing pain and other side effects: a systematic review of randomized controlled trials. Can J Anaesth 60, 907-917. Dunford, P.J., Williams, K.N., Desai, P.J., Karlsson, L., McQueen, D., and Thurmond, R.L. (2007). Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 119, 176-183. Duque, M.I., Thevarajah, S., Chan, Y.H., Tuttle, A.B., Freedman, B.I., and Yosipovitch, G. (2006). Uremic pruritus is associated with higher kt/V and serum calcium concentration. Clin Nephrol 66, 184-191. Duque, M.I., Yosipovitch, G., Fleischer, A.B., Jr., Willard, J., and Freedman, B.I. (2005). Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol 52, 519-521. Duval, A., and Dubertret, L. (2009). Aprepitant as an antipruritic agent? N Engl J Med 361, 1415-1416. Dyachenko, P., Shustak, A., and Rozenman, D. (2006). Hemodialysis-related pruritus and associated cutaneous manifestations. Int J Dermatol 45, 664-667. Eberlein, B., Eicke, C., Reinhardt, H.W., and Ring, J. (2008). Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol 22, 73-82. Eknoyan, G., Beck, G.J., Cheung, A.K., Daugirdas, J.T., Greene, T., Kusek, J.W., Allon, M., Bailey, J., Delmez, J.A., Depner, T.A., et al. (2002). Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347, 2010-2019. el-Ghorr, A.A., and Norval, M. (1997). Biological effects of narrow-band (311 nm TL01) UVB irradiation: a review. J Photochem Photobiol B 38, 99-106. El-Ghorr, A.A., Pierik, F., and Norval, M. (1994). Comparative potency of different UV sources in reducing the density and antigen-presenting capacity of Langerhans cells in C3H mice. Photochem Photobiol 60, 256-261. Elliott, J., Tesfaye, S., Chaturvedi, N., Gandhi, R.A., Stevens, L.K., Emery, C., and Fuller, J.H. (2009). Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care 32, 1896-1900. Engelhardt, H., Smits, R.A., Leurs, R., Haaksma, E., and de Esch, I.J. (2009). A new generation of anti-histamines: Histamine H4 receptor antagonists on their way to the clinic. Curr Opin Drug Discov Devel 12, 628-643. Evans, P.R. (1976). Referred itch (Mitempfindungen). Br Med J 2, 839-841. Ezzat, M.H., Hasan, Z.E., and Shaheen, K.Y. (2011). Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol 25, 334-339. Ferringer, T., and Miller, F., 3rd (2002). Cutaneous manifestations of diabetes mellitus. Dermatol Clin 20, 483-492. Finlay, A.Y., and Khan, G.K. (1994). Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 19, 210-216. Flor, H., Knost, B., and Birbaumer, N. (2002). The role of operant conditioning in chronic pain: an experimental investigation. Pain 95, 111-118. Francos, G.C., Kauh, Y.C., Gittlen, S.D., Schulman, E.S., Besarab, A., Goyal, S., and Burke, J.F., Jr. (1991). Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. Int J Dermatol 30, 884-889. Fritsche, E., Schafer, C., Calles, C., Bernsmann, T., Bernshausen, T., Wurm, M., Hubenthal, U., Cline, J.E., Hajimiragha, H., Schroeder, P., et al. (2007). Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proc Natl Acad Sci U S A 104, 8851-8856. Frost, D., and Beischer, W. (2001). Limited joint mobility in type 1 diabetic patients: associations with microangiopathy and subclinical macroangiopathy are different in men and women. Diabetes Care 24, 95-99. Furue, M., Ebata, T., Ikoma, A., Takeuchi, S., Kataoka, Y., Takamori, K., Satoh, T., Saeki, H., Augustin, M., Reich, A., et al. (2013). Verbalizing Extremes of the Visual Analogue Scale for Pruritus: A Consensus Statement. Acta Derm Venereol 93, 214-215. Gambichler, T., Breuckmann, F., Boms, S., Altmeyer, P., and Kreuter, A. (2005). Narrowband UVB phototherapy in skin conditions beyond psoriasis. J Am Acad Dermatol 52, 660-670. Gandek, B., Ware, J.E., Aaronson, N.K., Apolone, G., Bjorner, J.B., Brazier, J.E., Bullinger, M., Kaasa, S., Leplege, A., Prieto, L., et al. (1998). Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 51, 1171-1178. Garssen, J., Vandebriel, R.J., De Gruijl, F.R., Wolvers, D.A., Van Dijk, M., Fluitman, A., and Van Loveren, H. (1999). UVB exposure-induced systemic modulation of Th1- and Th2-mediated immune responses. Immunology 97, 506-514. Gaspari, A.A., Lotze, M.T., Rosenberg, S.A., Stern, J.B., and Katz, S.I. (1987). Dermatologic changes associated with interleukin 2 administration. JAMA 258, 1624-1629. Gerrits, E.G., Lutgers, H.L., Kleefstra, N., Graaff, R., Groenier, K.H., Smit, A.J., Gans, R.O., and Bilo, H.J. (2008). Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 31, 517-521. Gibbs, N.K., Norval, M., Traynor, N.J., Crosby, J.C., Lowe, G., and Johnson, B.E. (1993). Comparative potency of broad-band and narrow-band phototherapy sources to induce edema, sunburn cells and urocanic acid photoisomerization in hairless mouse skin. Photochem Photobiol 58, 643-647. Gilchrest, B.A., Rowe, J.W., Brown, R.S., Steinman, T.I., and Arndt, K.A. (1977). Relief of uremic pruritus with ultraviolet phototherapy. N Engl J Med 297, 136-138. Gilchrest, B.A., Rowe, J.W., Brown, R.S., Steinman, T.I., and Arndt, K.A. (1979). Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 91, 17-21. Giovannetti, S., Barsotti, G., Cupisti, A., Dani, L., Bandini, S., Angelini, D., Antonelli, A., Salvadori, M., and Urti, D.A. (1995). Oral activated charcoal in patients with uremic pruritus. Nephron 70, 193-196. Goldsmith, L., Katz, S., Gilchrest, B., Paller, A., Leffell, D., and Wolff, K. (2012). Fitzpatrick's Dermatology in General Medicine, Eighth Edition, 2 Volume set (Mcgraw-hill). Goswami, R., Dadhwal, V., Tejaswi, S., Datta, K., Paul, A., Haricharan, R.N., Banerjee, U., and Kochupillai, N.P. (2000). Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect 41, 162-166. Graf, H., Kovarik, J., Stummvoll, H.K., and Wolf, A. (1979). Disappearance of uraemic pruritus after lowering dialysate magnesium concentration. Br Med J 2, 1478-1479. Groneberg, D.A., Serowka, F., Peckenschneider, N., Artuc, M., Grutzkau, A., Fischer, A., Henz, B.M., and Welker, P. (2005). Gene expression and regulation of nerve growth factor in atopic dermatitis mast cells and the human mast cell line-1. J Neuroimmunol 161, 87-92. Grothe, C., Heese, K., Meisinger, C., Wewetzer, K., Kunz, D., Cattini, P., and Otten, U. (2000). Expression of interleukin-6 and its receptor in the sciatic nerve and cultured Schwann cells: relation to 18-kD fibroblast growth factor-2. Brain Res 885, 172-181. Gunal, A.I., Ozalp, G., Yoldas, T.K., Gunal, S.Y., Kirciman, E., and Celiker, H. (2004). Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrology Dialysis Transplantation 19, 3137-3139. Halvorson, K.G., Kubota, K., Sevcik, M.A., Lindsay, T.H., Sotillo, J.E., Ghilardi, J.R., Rosol, T.J., Boustany, L., Shelton, D.L., and Mantyh, P.W. (2005). A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 65, 9426-9435. Han, C.L., Chen, J.S., Chan, E.C., Wu, C.P., Yu, K.H., Chen, K.T., Tsou, C.C., Tsai, C.F., Chien, C.W., Kuo, Y.B., et al. (2011). An informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer. Mol Cell Proteomics 10, M110 003087. Hastie, T., and Tibshirani, R. (1990). The gam Package. London: Chapman and Hall. Hastie, T.J., and Tibshirani, R. (1991). Generalized additive models. Chapter 7 of Statistical Models in S eds J M Chambers and T J Hastie, Pacific Grove, CA: Wadsworth & Brooks/Cole. Hayashi, Y., and Aurelian, L. (1986). Immunity to herpes simplex virus type 2: viral antigen-presenting capacity of epidermal cells and its impairment by ultraviolet irradiation. J Immunol 136, 1087-1092. Hearn, R.M., Kerr, A.C., Rahim, K.F., Ferguson, J., and Dawe, R.S. (2008). Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 159, 931-935. Hemodialysis Adequacy 2006 Work Group (2006). Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 48 Suppl 1, S2-90. Hillson, R.M., Hockaday, T.D., Newton, D.J., and Pim, B. (1985). Delayed diagnosis of non-insulin-dependent diabetes is associated with greater metabolic and clinical abnormality. Diabet Med 2, 383-386. Hindson, C., Taylor, A., Martin, A., and Downey, A. (1981). UVA light for relief of uraemic pruritus. Lancet 1, 215. Hiroshige, K., Kabashima, N., Takasugi, M., and Kuroiwa, A. (1995). Optimal dialysis improves uremic pruritus. Am J Kidney Dis 25, 413-419. Hsieh, J.C., Hagermark, O., Stahle-Backdahl, M., Ericson, K., Eriksson, L., Stone-Elander, S., and Ingvar, M. (1994). Urge to scratch represented in the human cerebral cortex during itch. J Neurophysiol 72, 3004-3008. Hsu, M.M., and Yang, C.C. (2003). Uraemic pruritus responsive to broadband ultraviolet (UV) B therapy does not readily respond to narrowband UVB therapy. Br J Dermatol 149, 888-889. Hundley, J.L., and Yosipovitch, G. (2004). Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol 50, 889-891. Hwang, S.W., Cho, H., Kwak, J., Lee, S.Y., Kang, C.J., Jung, J., Cho, S., Min, K.H., Suh, Y.G., Kim, D., et al. (2000). Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A 97, 6155-6160. Ikoma, A., Steinhoff, M., Stander, S., Yosipovitch, G., and Schmelz, M. (2006). The neurobiology of itch. Nat Rev Neurosci 7, 535-547. Inan, S., and Cowan, A. (2004). Kappa opioid agonists suppress chloroquine-induced scratching in mice. Eur J Pharmacol 502, 233-237. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A.L., Tsapas, A., Wender, R., and Matthews, D.R. (2012). Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55, 1577-1596. Ishikawa, C., Tsuda, T., Konishi, H., Nakagawa, N., and Yamanishi, K. (2009). Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes. Antimicrob Agents Chemother 53, 1760-1765. Johanek, L.M., Meyer, R.A., Friedman, R.M., Greenquist, K.W., Shim, B., Borzan, J., Hartke, T., LaMotte, R.H., and Ringkamp, M. (2008). A role for polymodal C-fiber afferents in nonhistaminergic itch. J Neurosci 28, 7659-7669. Johanek, L.M., and Simone, D.A. (2004). Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. Pain 109, 432-442. Johansson, O., Hilliges, M., and Stahle-Backdahl, M. (1989). Intraepidermal neuron-specific enolase (NSE)-immunoreactive nerve fibres: evidence for sprouting in uremic patients on maintenance hemodialysis. Neurosci Lett 99, 281-286. Johansson, O., Liang, Y., and Emtestam, L. (2002). Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin -- an exploration of the cause of neurohyperplasia. Arch Dermatol Res 293, 614-619. Joshi, N., Caputo, G.M., Weitekamp, M.R., and Karchmer, A.W. (1999). Infections in patients with diabetes mellitus. N Engl J Med 341, 1906-1912. Kawagoe, J., Takizawa, T., Matsumoto, J., Tamiya, M., Meek, S.E., Smith, A.J., Hunter, G.D., Plevin, R., Saito, N., Kanke, T., et al. (2002). Effect of protease-activated receptor-2 deficiency on allergic dermatitis in the mouse ear. Jpn J Pharmacol 88, 77-84. Kaysen, G.A. (2001). The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 12, 1549-1557. Kim, H.S., and Yosipovitch, G. (2013). An aberrant parasympathetic response: a new perspective linking chronic stress and itch. Exp Dermatol 22, 239-244. Kimmel, M., Alscher, D.M., Dunst, R., Braun, N., Machleidt, C., Kiefer, T., Stulten, C., van der Kuip, H., Pauli-Magnus, C., Raub, U., et al. (2006). The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant 21, 749-755. Klein, L.R., Klein, J.B., Hanno, R., and Callen, J.P. (1988). Cutaneous mast cell quantity in pruritic and nonpruritic hemodialysis patients. Int J Dermatol 27, 557-559. Knutson, K.L., Ryden, A.M., Mander, B.A., and Van Cauter, E. (2006). Role of sleep duration and quality in the risk and severity of type 2 diabetes mellitus. Arch Intern Med 166, 1768-1774. Ko, M.C., and Husbands, S.M. (2009). Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther 328, 193-200. Ko, M.J., Chiu, H.C., Jee, S.H., Hu, F.C., and Tseng, C.H. (2013a). Postprandial blood glucose is associated with generalized pruritus in patients with type 2 diabetes. Eur J Dermatol. Ko, M.J., Wu, H.Y., Chen, H.Y., Chiu, Y.L., Hsu, S.P., Pai, M.F., Ju, Y., Lai, C.F., Lu, H.M., Huang, S.C., et al. (2013b). Uremic pruritus, dialysis adequacy, and metabolic profiles in hemodialysis patients: a prospective 5-year cohort study. PLoS One 8, e71404. Ko, M.J., Yang, J.Y., Wu, H.Y., Hu, F.C., Chen, S.I., Tsai, P.J., Jee, S.H., and Chiu, H.C. (2011). Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. British Journal of Dermatology 165, 633-639. Kobayashi, H., Gleich, G.J., Butterfield, J.H., and Kita, H. (2002). Human eosinophils produce neurotrophins and secrete nerve growth factor on immunologic stimuli. Blood 99, 2214-2220. Koda, Y., Nishi, S., Miyazaki, S., Haginoshita, S., Sakurabayashi, T., Suzuki, M., Sakai, S., Yuasa, Y., Hirasawa, Y., and Nishi, T. (1997). Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52, 1096-1101. Koplas, P.A., Rosenberg, R.L., and Oxford, G.S. (1997). The role of calcium in the desensitization of capsaicin responses in rat dorsal root ganglion neurons. J Neurosci 17, 3525-3537. Kringelbach, M.L. (2005). The human orbitofrontal cortex: linking reward to hedonic experience. Nat Rev Neurosci 6, 691-702. Krutmann, J., Czech, W., Diepgen, T., Niedner, R., Kapp, A., and Schopf, E. (1992). High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 26, 225-230. Kuypers, D.R. (2009). Skin problems in chronic kidney disease. Nat Clin Pract Nephrol 5, 157-170. Kyriazis, J., and Glotsos, J. (2000). Dialysate calcium concentration of</=1.25 mmol/l: is it effective in suppressing uremic pruritus? Nephron 84, 85-86. Laihinen, A. (1991). Assessment of psychiatric and psychosocial factors disposing to chronic outcome of dermatoses. Acta Derm Venereol Suppl (Stockh) 156, 46-48. Lane, N.E., Schnitzer, T.J., Birbara, C.A., Mokhtarani, M., Shelton, D.L., Smith, M.D., and Brown, M.T. (2010). Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 363, 1521-1531. Li, S.W., Yang, T.C., Wan, L., Lin, Y.J., Tsai, F.J., Lai, C.C., and Lin, C.W. (2012). Correlation between TGF-beta1 expression and proteomic profiling induced by severe acute respiratory syndrome coronavirus papain-like protease. Proteomics 12, 3193-3205. Liang, K.-Y., and Zeger, S.L. (1986). Longitudinal Data Analysis Using Generalized Linear Models. Biometrika 73, 13-22. Lim, G.J., Ishiuji, Y., Dawn, A., Harrison, B., Kim do, W., Atala, A., and Yosipovitch, G. (2008). In vitro and in vivo characterization of a novel liposomal butorphanol formulation for treatment of pruritus. Acta Derm Venereol 88, 327-330. Locatelli, F., and Canaud, B. (2012). Dialysis adequacy today: a European perspective. Nephrol Dial Transplant 27, 3043-3048. Magerl, W., Westerman, R.A., Mohner, B., and Handwerker, H.O. (1990). Properties of transdermal histamine iontophoresis: differential effects of season, gender, and body region. Journal of investigative dermatology 94, 347-352. Masi, C.M., and Cohen, E.P. (1992). Dialysis efficacy and itching in renal failure. Nephron 62, 257-261. Massry, S.G., Popovtzer, M.M., Coburn, J.W., Makoff, D.L., Maxwell, M.H., and Kleeman, C.R. (1968). Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy. N Engl J Med 279, 697-700. Mathur, V.S., Lindberg, J., Germain, M., Block, G., Tumlin, J., Smith, M., Grewal, M., and McGuire, D. A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol 5, 1410-1419. Mathur, V.S., Lindberg, J., Germain, M., Block, G., Tumlin, J., Smith, M., Grewal, M., and McGuire, D. (2010). A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol 5, 1410-1419. McCarney, R., Warner, J., Iliffe, S., van Haselen, R., Griffin, M., and Fisher, P. (2007). The Hawthorne Effect: a randomised, controlled trial. BMC Med Res Methodol 7, 30. McEwen, B.S. (2012). Brain on stress: how the social environment gets under the skin. Proc Natl Acad Sci U S A 109 Suppl 2, 17180-17185. Meigs, J.B., Nathan, D.M., D'Agostino, R.B., Sr., and Wilson, P.W. (2002). Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25, 1845-1850. Mettang, T., Fritz, P., Weber, J., Machleidt, C., Hubel, E., and Kuhlmann, U. (1990). Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). The role of plasma histamine and skin mast cells. Clin Nephrol 34, 136-141. Mettang, T., Pauli-Magnus, C., and Alscher, D.M. (2002). Uraemic pruritus--new perspectives and insights from recent trials. Nephrol Dial Transplant 17, 1558-1563. Metz, M., Lammel, V., Gibbs, B.F., and Maurer, M. (2006). Inflammatory murine skin responses to UV-B light are partially dependent on endothelin-1 and mast cells. Am J Pathol 169, 815-822. Mistik, S., Utas, S., Ferahbas, A., Tokgoz, B., Unsal, G., Sahan, H., Ozturk, A., and Utas, C. (2006). An epidemiology study of patients with uremic pru | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58832 | - |
| dc.description.abstract | 搔癢是皮膚疾病的主要症狀，也常是全身性疾病的表現。皮膚搔癢症可引起嚴重不適、焦慮、抑鬱、睡眠問題、皮膚損害，並影響生活品質。
廣泛性搔癢症，定義為大範圍的皮膚搔癢但沒有原發性皮疹，發生於約3％到50％的糖尿病患。較早的研究報告指出糖尿病婦女有較高的陰部搔癢症，但罹患廣泛性搔癢症與糖化血色素並沒有相關。最近的研究則顯示，糖尿病患者比起非糖尿病患者有較高的比率發生不明原因軀幹部位的搔癢，並與糖尿病的多發神經病變相關。 我們執行一橫斷式研究，由糖尿病照護系統招募第2型糖尿病的患者。由皮膚科醫師執行皮膚檢查，並使用詳細的問卷，包括視覺模擬評分法，評估搔癢的特性及強度。最後，利用羅吉斯迴歸分析，研究飯後血糖、飯前血糖和糖化血紅素與廣泛性搔癢症之關係。 這個研究招募了385位糖尿病患者，106位(27.5％)患有廣泛性搔癢症。其中，因為搔癢，24.5％有入睡困難，15.1％有睡眠障礙，9.5％需要助眠劑。第2型糖尿病患者若飯後血糖較高，患有廣泛性搔癢症的風險也較高〔OR=1.41（95％ C.I.：1.05–1.90）, P=0.02〕。 研究結果顯示第2型糖尿病患者之廣泛性搔癢症與飯後血糖控制相關。此結果可提醒臨床醫師關注糖尿病患者的搔癢症狀，並使患者更有動機做好血糖控制。 尿毒性搔癢症是慢性腎臟病患者常見且困擾的症狀，接受長期透析約有百分之四十至九十的病人有此症狀。至今，尿毒性搔癢症的機制尚不清楚。許多尿毒性皮膚搔癢症患者有極長之病程，且搔癢強度過程中可能會有高低，但缺乏相關的縱向追蹤研究。 為了解決這個問題，我們執行了一項前瞻性、追蹤5年的世代研究，探討血液透析患者搔癢強度加重或緩解的預測因子。此縱向追蹤研究，透過change score analysis考慮每個共變項的變化，分析搔癢強度、代謝概況以及透析充分性的關係。並使用廣義加法模型（generalized additive models)及receiver operating characteristic曲線決定透析廓清率（Kt/V）的最佳閥值。 共111例患者完成這項研究。線性迴歸分析顯示，調整基礎搔癢強度和干擾因子後，較低之透析廓清率（Kt/V）及使用低透量透析器與搔癢加重有顯著的相關。廣義加法模型及receiver operating characteristic曲線建議之最佳Kt/V閥值皆約為1.5。此閥值略高於目前以減少死亡率為目標的臨床準則之數值。研究結果顯示，Kt/V值高於當前的標準，雖不能進一步降低死亡率，但可能可以提高生活品質。這也暗示著致癢物質的清除可能影響搔癢的強度。 尿毒性搔癢症的治療方式至今仍是相當有限。寬頻紫外光B光照療法已被證實可有效治療尿毒性搔癢症。因為窄頻紫外光B光照療法在乾癬的治療更為有效，近年來，逐漸以窄頻紫外光B光照療法取代寬頻紫外光B光照療法。但關於窄頻紫外光B光照療法對尿毒性搔癢症的研究非常少。 因此，我們執行了一個單盲、隨機控制之臨床試驗，評估窄頻紫外光B光照療法對減輕尿毒性搔癢症之療效。納入的受試者為大於18歲，慢性腎臟病第3期至第5期或第5期D之成年人。受試者之搔癢強度須以視覺模擬評分法評估超過5分，搔癢病程超過2個月，並對口服抗組織胺及局部藥物治療反應不佳。治療組接受全身窄頻紫外光B光照療法，每周3次，共6周。起始劑量由210 mJ/cm2逐漸增加。控制組接受相同時間的長波長紫外光A光，劑量約1-6 J/cm2。治療前及第6週使用問卷評估皮膚搔癢的詳細情形，並且每週評估皮膚搔癢的強度至第12週。 治療組、控制組患者搔癢的程度在治療及追蹤期間皆有顯著的進步。然而，兩組間並無統計學上顯著的差異。使用效力更佳的統計方式分析，顯示搔癢的程度在治療結束時(第6週)及追蹤時(第10、12週)，窄頻紫外光B光照療法比起控制組有統計上顯著的差異，但其效果有限。相較於治療前，第6週時治療組搔癢影響之體表面積有顯著的進步，但控制組則無此效果。治療組及控制組在治療前及第6週時，關於睡眠品質的評估，沒有達到顯著的差異。 此研究中，我們沒有發現窄頻紫外光B光照療法比起控制組，對尿毒性搔癢症有顯著的療效。這不同於前人的研究發現寬頻紫外光B光照療法對尿毒性搔癢症有效。因此，雖然窄頻紫外光B光照療法已證明比寬頻紫外光B光照療法更有效地治療乾癬，其優異的效果無法直接推論於其他光照治療有效的皮膚疾病，如：尿毒性搔癢症。 | zh_TW |
| dc.description.abstract | Pruritus is the dominant symptom of skin disease and a frequent manifestation of systemic disease. It causes serious discomfort, anxiety, depression, sleeping disorders, considerable skin damagend and has substantial effects on quality of life.
We conducted a cross-sectional study to investigate the association of glycemic control with generalized pruritus in type 2 diabetes. A total of 385 patients with type 2 diabetes who attended the diabetes care system underwent cutaneous examination by a dermatologist. A detailed interview questionnaire including visual analogue scale was used to assess various characteristics and the intensity of pruritus. Generalized pruritus was noted in 27.5% of the diabetic patients. As a result of pruritus, 24.5% of the patients had difficulties in falling asleep, 15.1% had disturbance of sleep, and 9.5% needed soporifics. Patients who had a higher postprandial glucose level had a higher probability of having generalized pruritus [OR=1.41 (95% C.I.: 1.05–1.90), P=0.02] in type 2 diabetic patients. We found generalized pruritus in patients with type 2 diabetes mellitus is associated with PC glucose control. This finding arouses the physicians to pay more attention to pruritus in diabetic patients and to motivate the patient for better blood glucose control. Uremic pruritus is also one of the most common and bothersome symptoms in patients with chronic kidney disease, with approximately 40-90% of patients on long-term maintenance dialysis suffering from this problem. To date, the mechanisms of uremic pruritus remain poorly characterized. We conducted a prospective cohort study of patients with maintenance hemodialysis in the hemodialysis center. Patient demographic and clinical characteristics, laboratory parameters, dialysis adequacy (assessed by Kt/V), and pruritus intensity were recorded at baseline and follow-up. Change score analysis of the difference score of VAS between baseline and follow-up was performed using multiple linear regression models. A total of 111 patients completed the study. Linear regression analysis showed that lower Kt/V and use of low-flux dialyzer were significantly associated with the aggravation of pruritus after adjusting for the baseline pruritus intensity and a variety of confounding factors. The optimal threshold value of Kt/V for pruritus was 1.5 suggested by both generalized additive models and receiver operating characteristic analysis. The cut-off value of 1.5 for Kt/V suggested by our study for pruritus is slightly above the target levels reducing mortality recommended in clinical practice guidelines, which not only implies that a Kt/V higher than the current standard may not further improve survival but may improve the quality of life, but also indicates that the clearance of pruritogenic substances could influence the intensity of pruritus. The therapeutic options for uremic pruritus are limited and unsatisfactory. Broad band ultraviolet B phototherapy has been demonstrated to be effective in the treatment of uremic pruritus in previous studies. Recently there is a trend of replacing BB-UVB phototherapy units with narrowband ultraviolet B (NB-UVB) units, as studies have demonstrated that NB-UVB is more efficacious in the treatment of psoriasis. However, studies regarding NB-UVB phototherpy for uremic pruritus are rare. A single blinded, randomized control trial was conducted to investigate the efficacy of NB-UVB phototherapy in uremic pruritus. Eligible participants were adults older than 18 years old, with CKD stage 3 to 5 and 5D. Patients with pruritus of visual analogue scale score over 5, itching duration of more than 2 months, and refractory to oral antihistamines and topical emollients were enrolled. The treatment group received NB-UVB phototherapy 3 times per week for 6 weeks. The dose of NB-UVB started from 210 mJ/cm2 and was increased by 10% at each time. The control group received time-matched exposures to long-wave ultraviolet light (UVA).Visual analogue scale score was evaluated weekly for pruritus intensity for 12 weeks. The characteristics of pruritus were also assessed by a questionnaire at baseline and after 6-week phototherapy. Both NB-UVB and control groups have significant and comparable improvement in the pruritus intensity VAS scores during the period of phototherapy and follow-up. Compared to control group, the NB-UVB group showed a significant improvement in the involved body surface area affected by pruritus (p = 0.006), but not in sleep quality. More detailed regression and estimating analysis revealed that the patients in the NB-UVB group had lower pruritus intensity at week 6, week 10, and week 12. This may indicate a beneficial difference at certain time points, but the effect seems marginal. NB-UVB phototherapy does not show a significant effect in reducing pruritus intensity compared to control group for refractory uremic pruritus. This finding may imply that although NB-UVB has been demonstrated to be more effective than BB-UVB for the treatment of psoriasis, its superior effect should not be directly extrapolated to other potential phototherapy-responsive dermatoses, such as uremic pruritus in this study. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T08:33:36Z (GMT). No. of bitstreams: 1 ntu-102-Q95421012-1.pdf: 1921483 bytes, checksum: 966533b000ea90ac1ab1699eb7346a6f (MD5) Previous issue date: 2013 | en |
| dc.description.tableofcontents | 第一章、 緒論............................................1
第一節 癢的臨床及生理基礎 ...............................1 第二節 糖尿病患之廣泛性搔癢症及其與血糖控制之相關性...........11 第三節 尿毒性搔癢症的病理生理機轉......................... 13 第四節 光照療法治療尿毒性搔癢症........................... 15 研究的目的...............................................22 第二章、 研究方法與材料....................................23 第一節 糖尿病患之廣泛性搔癢症及其與血糖控制之相關性............23 第二節 縱向追蹤研究尿毒性搔癢症的病理生理機轉................. 25 第三節 窄頻紫外光B光照療法治療尿毒性搔癢症：隨機臨床試驗........28 第三章、 結果............................................ 31 第一節 糖尿病患之廣泛性搔癢症及其與血糖控制之相關性............31 第二節 縱向追蹤研究尿毒性搔癢症的病理生理機轉 ................32 第三節 窄頻紫外光B光照療法治療尿毒性搔癢症：隨機臨床試驗........34 第四章、 討論.............................................37 第一節 糖尿病患之廣泛性搔癢症及其與血糖控制之相關性............ 38 第二節 縱向追蹤研究尿毒性搔癢症的病理生理機轉................. 45 第三節 窄頻紫外光B光照療法治療尿毒性搔癢症：隨機臨床試驗....... 51 第五章、 展望............................................ 58 第六章、 論文英文簡述(summary)............................. 68 第七章、 參考文獻......................................... 82 第八章、 圖表............................................ 104 第九章、 附錄............................................ 127 | |
| dc.language.iso | zh-TW | |
| dc.subject | 尿毒性搔癢症 | zh_TW |
| dc.subject | 透析充分性 | zh_TW |
| dc.subject | 高血糖 | zh_TW |
| dc.subject | 血糖控制 | zh_TW |
| dc.subject | 透析廓清率 | zh_TW |
| dc.subject | 光照療法 | zh_TW |
| dc.subject | 窄頻紫外光 | zh_TW |
| dc.subject | 癢 | zh_TW |
| dc.subject | 糖尿病 | zh_TW |
| dc.subject | Itching | en |
| dc.subject | Kt/V | en |
| dc.subject | Phototherapy | en |
| dc.subject | Narrowband UVB | en |
| dc.subject | Uremic pruritus | en |
| dc.subject | Diabetes Mellitus | en |
| dc.subject | Glycemic Control | en |
| dc.subject | Hyperglycemia | en |
| dc.subject | Pruritus | en |
| dc.subject | Dialysis adequacy | en |
| dc.title | 皮膚搔癢症：機制與治療 | zh_TW |
| dc.title | Pruritus：Mechanism and Treatment | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-1 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 楊偉勛,邱顯清,黃奇英,余兆松 | |
| dc.subject.keyword | 癢,高血糖,血糖控制,糖尿病,尿毒性搔癢症,透析充分性,透析廓清率,光照療法,窄頻紫外光, | zh_TW |
| dc.subject.keyword | Itching,Pruritus,Hyperglycemia,Glycemic Control,Diabetes Mellitus,Uremic pruritus,Dialysis adequacy,Kt/V,Phototherapy,Narrowband UVB, | en |
| dc.relation.page | 127 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2013-12-04 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
| 顯示於系所單位： | 臨床醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-102-1.pdf 未授權公開取用 | 1.88 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。